Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin for prevention of taxane-induced peripheral neuropathy in breast cancer
IRCT20160310026998N14Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of melatonin in taxane-induced peripheral neuropathy (TIPN) and breast cancer, sponsored by Tabriz University of Medical Sciences. Primary endpoint: Incidence of taxane-induced peripheral neuropathy. Started Dec 2023; status: completed.
02
Drugs
melatonin
03
Conditions
taxane-induced peripheral neuropathy (TIPN)breast cancer
Beyond the preview
Go deeper on IRCT20160310026998N14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160310026998N14.